USP5 promotes tumor progression by stabilizing SLUG in bladder cancer

Wan,Qiang-Kun; Li,Ting-Ting; Liu,Bei-Bei; He,Bin

doi:10.3892/ol.2024.14705

USP5 promotes tumor progression by stabilizing SLUG in bladder cancer

Authors:
- Qiang-Kun Wan
- Ting-Ting Li
- Bei-Bei Liu
- Bin He
View Affiliations

Affiliations: Department of Radiotherapy, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, P.R. China, Department of Urology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, P.R. China
Published online on: September 27, 2024 https://doi.org/10.3892/ol.2024.14705
Article Number: 572
Copyright: © Wan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bladder cancer ranks as the second most prevalent urology malignancy globally. Invasive metastasis is a significant contributor to mortality among patients with bladder cancer, yet the underlying mechanisms remain elusive. Deubiquitinases are pivotal in carcinogenesis, with USP5 implicated in the malignant progression of hepatocellular carcinoma, colorectal cancer and non‑small cell lung cancer. The present study assessed the role and mechanism of ubiquitin‑specific proteinase 5 (USP5) in the malignant progression of bladder cancer. The association between USP5 expression and bladder cancer prognosis and stage was analyzed using The Cancer Genome Atlas database. Moreover, to elucidate the role of USP5 in bladder cancer, USP5 overexpression and knockdown cell lines were established using T24 cells. Cell viability, proliferation and migration were assessed using Cell Counting Kit‑8, Transwell and scratch assays, respectively. Cyclohexanamide was used to evaluate the effect of USP5 expression on Snail family zinc finger 2 (SLUG) stability. Immunoprecipitation and immunofluorescence co‑localization were utilized to probe the interaction between USP5 and SLUG. Changes in mRNA and protein levels were assessed using reverse transcription‑quantitative PCR and western blotting, respectively. The results revealed that patients with bladder cancer with high USP5 expression had significantly shorter survival (P<0.05) and a higher clinicopathologic stage (P<0.05) than those with low USP5 expression. T24 cells overexpressing USP5 demonstrated significantly increased proliferation (P<0.05), invasion (P<0.05) and expression of epithelial‑mesenchymal transition markers (P<0.05); whereas T24 cells with knocked‑down USP5 expression revealed significantly reduced proliferation (P<0.05), invasion (P<0.05) and epithelial‑mesenchymal transition markers (P<0.05). Immunoprecipitation experiments demonstrated the binding of USP5 to SLUG in bladder cancer cells, with further analysis revealing that USP5 upregulated protein levels of SLUG by inhibiting its ubiquitination. Furthermore, the treatment of bladder cancer cells with Degrasyn, a USP5 inhibitor, was associated with a significant inhibition of the proliferation (P<0.05) and invasion (P<0.05) of T24 cells. In conclusion, the findings of the present study underscore the role of USP5 in promoting the malignant progression of bladder cancer through the stabilization of SLUG. Targeting USP5 holds promise as a strategy for inhibiting bladder cancer progression.

View Figures

View References

1	Dyrskjøt L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J and Theodorescu D: Bladder cancer. Nat Rev Dis Primers. 9:582023. View Article : Google Scholar : PubMed/NCBI
2	Lopez-Beltran A, Cookson MS, Guercio BJ and Cheng L: Advances in diagnosis and treatment of bladder cancer. BMJ. 384:e0767432024. View Article : Google Scholar : PubMed/NCBI
3	Jubber I, Ong S, Bukavina L, Black PC, Compérat E, Kamat AM, Kiemeney L, Lawrentschuk N, Lerner SP, Meeks JJ, et al: Epidemiology of bladder cancer in 2023: A systematic review of risk factors. Eur Urol. 84:176–190. 2023. View Article : Google Scholar : PubMed/NCBI
4	Lange SM, Armstrong LA and Kulathu Y: Deubiquitinases: From mechanisms to their inhibition by small molecules. Mol Cell. 82:15–29. 2022. View Article : Google Scholar : PubMed/NCBI
5	Ren J, Yu P, Liu S, Li R, Niu X, Chen Y, Zhang Z, Zhou F and Zhang L: Deubiquitylating enzymes in cancer and immunity. Adv Sci (Weinh). 10:e23038072023. View Article : Google Scholar : PubMed/NCBI
6	Nelson JK, Thin MZ, Evan T, Howell S, Wu M, Almeida B, Legrave N, Koenis DS, Koifman G, Sugimoto Y, et al: USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer. Nat Commun. 13:20702022. View Article : Google Scholar : PubMed/NCBI
7	Park HB and Baek KH: Current and future directions of USP7 interactome in cancer study. Biochim Biophys Acta Rev Cancer. 1878:1889922023. View Article : Google Scholar : PubMed/NCBI
8	Chang G, Xie GS, Ma L, Li P, Li L and Richard HT: USP36 promotes tumorigenesis and drug sensitivity of glioblastoma by deubiquitinating and stabilizing ALKBH5. Neuro Oncol. 25:841–853. 2023. View Article : Google Scholar : PubMed/NCBI
9	Tang J, Long G, Hu K, Xiao D, Liu S, Xiao L, Zhou L and Tao Y: Targeting USP8 inhibits O-GlcNAcylation of SLC7A11 to promote ferroptosis of hepatocellular carcinoma via stabilization of OGT. Adv Sci (Weinh). 10:e23029532023. View Article : Google Scholar : PubMed/NCBI
10	Ning F, Xin H, Liu J, Lv C, Xu X, Wang M, Wang Y, Zhang W and Zhang X: Structure and function of USP5: Insight into physiological and pathophysiological roles. Pharmacol Res. 157:1045572020. View Article : Google Scholar : PubMed/NCBI
11	Dewson G, Eichhorn PJA and Komander D: Deubiquitinases in cancer. Nat Rev Cancer. 23:842–862. 2023. View Article : Google Scholar : PubMed/NCBI
12	Yan B, Guo J, Deng S, Chen D and Huang M: A pan-cancer analysis of the role of USP5 in human cancers. Sci Rep. 13:89722023. View Article : Google Scholar : PubMed/NCBI
13	Meng J, Ai X, Lei Y, Zhong W, Qian B, Qiao K, Wang X, Zhou B, Wang H, Huai L, et al: USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma. Theranostics. 9:573–587. 2019. View Article : Google Scholar : PubMed/NCBI
14	Huang W, Liu X, Zhang Y, Deng M, Li G, Chen G, Yu L, Jin L, Liu T, Wang Y and Chen Y: USP5 promotes breast cancer cell proliferation and metastasis by stabilizing HIF2α. J Cell Physiol. 237:2211–2219. 2022. View Article : Google Scholar : PubMed/NCBI
15	Zhang Z, Cui Z, Xie Z, Li C, Xu C, Guo X, Yu J, Chen T, Facchinetti F, Bohnenberger H, et al: Deubiquitinase USP5 promotes non-small cell lung cancer cell proliferation by stabilizing cyclin D1. Transl Lung Cancer Res. 10:3995–4011. 2021. View Article : Google Scholar : PubMed/NCBI
16	Akhmetkaliyev A, Alibrahim N, Shafiee D and Tulchinsky E: EMT/MET plasticity in cancer and Go-or-Grow decisions in quiescence: The two sides of the same coin? Mol Cancer. 22:902023. View Article : Google Scholar : PubMed/NCBI
17	Huang Y, Hong W and Wei X: The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 15:1292022. View Article : Google Scholar : PubMed/NCBI
18	Li D, Xia L, Huang P, Wang Z, Guo Q, Huang C, Leng W and Qin S: Heterogeneity and plasticity of epithelial-mesen-chymal transition (EMT) in cancer metastasis: Focusing on partial EMT and regulatory mechanisms. Cell Prolif. 56:e134232023. View Article : Google Scholar : PubMed/NCBI
19	Debnath P, Huirem RS, Dutta P and Palchaudhuri S: Epithelial-mesenchymal transition and its transcription factors. Biosci Rep. 42:BSR202117542022. View Article : Google Scholar : PubMed/NCBI
20	Chi M, Liu J, Mei C, Shi Y, Liu N, Jiang X, Liu C, Xue N, Hong H, Xie J, et al: TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer. J Exp Clin Cancer Res. 41:1752022. View Article : Google Scholar : PubMed/NCBI
21	Wang H, Mei Y, Luo C, Huang Q, Wang Z, Lu GM, Qin L, Sun Z, Huang CW, Yang ZW, et al: Single-cell analyses reveal mechanisms of cancer stem cell maintenance and epithelial-mesenchymal transition in recurrent bladder cancer. Clin Cancer Res. 27:6265–6278. 2021. View Article : Google Scholar : PubMed/NCBI
22	Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori G, et al: Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 21:341–352. 2020. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Cockram PE, Kist M, Prakash S, Chen SH, Wertz IE and Vucic D: Ubiquitination in the regulation of inflammatory cell death and cancer. Cell Death Differ. 28:591–605. 2021. View Article : Google Scholar : PubMed/NCBI
25	Deng L, Meng T, Chen L, Wei W and Wang P: The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 5:112020. View Article : Google Scholar : PubMed/NCBI
26	Xiao X, Shi J, He C, Bu X, Sun Y, Gao M, Xiang B, Xiong W, Dai P, Mao Q, et al: ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. Nat Commun. 14:28592023. View Article : Google Scholar : PubMed/NCBI
27	Pan J, Qiao Y, Chen C, Zang H, Zhang X, Qi F, Chang C, Yang F, Sun M, Lin S, et al: USP5 facilitates non-small cell lung cancer progression through stabilization of PD-L1. Cell Death Dis. 12:10512021. View Article : Google Scholar : PubMed/NCBI
28	Xia P, Zhang H, Lu H, Xu K, Jiang X, Jiang Y, Gongye X, Chen Z, Liu J, Chen X, et al: METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression. Cancer Commun (Lond). 43:338–364. 2023. View Article : Google Scholar : PubMed/NCBI
29	Cao L, Liu H, Huang C, Guo C, Zhao L, Gao C, Xu Y, Wang G, Liang N and Li S: USP5 knockdown alleviates lung cancer progression via activating PARP1-mediated mTOR signaling pathway. Biol Direct. 18:162023. View Article : Google Scholar : PubMed/NCBI
30	Pan S and Chen R: Pathological implication of protein post-translational modifications in cancer. Mol Aspects Med. 86:1010972022. View Article : Google Scholar : PubMed/NCBI
31	Lee JM, Hammarén HM, Savitski MM and Baek SH: Control of protein stability by post-translational modifications. Nat Commun. 14:2012023. View Article : Google Scholar : PubMed/NCBI
32	Li W, Shen M, Jiang YZ, Zhang R, Zheng H, Wei Y, Shao ZM and Kang Y: Deubiquitinase USP20 promotes breast cancer metastasis by stabilizing SNAI2. Genes Dev. 34:1310–1315. 2020. View Article : Google Scholar : PubMed/NCBI
33	Iwakami Y, Yokoyama S, Watanabe K and Hayakawa Y: STAM-binding protein regulates melanoma metastasis through SLUG stabilization. Biochem Biophys Res Commun. 507:484–488. 2018. View Article : Google Scholar : PubMed/NCBI
34	Liu SS, Qi J, Teng ZD, Tian FT, Lv XX, Li K, Song YJ, Xie WD, Hu ZW and Li X: Resistomycin attenuates triple-negative breast cancer progression by inhibiting E3 ligase Pellino-1 and inducing SNAIL/SLUG degradation. Signal Transduct Target Ther. 5:1332020. View Article : Google Scholar : PubMed/NCBI
35	Inoue Y, Itoh Y, Sato K, Kawasaki F, Sumita C, Tanaka T, Morishita D and Hayashi H: Regulation of epithelial-mesenchymal transition by E3 ubiquitin ligases and deubiquitinase in cancer. Curr Cancer Drug Targets. 16:110–118. 2016. View Article : Google Scholar : PubMed/NCBI
36	Ouchida AT, Kacal M, Zheng A, Ambroise G, Zhang B, Norberg E and Vakifahmetoglu-Norberg H: USP10 regulates the stability of the EMT-transcription factor Slug/SNAI2. Biochem Biophys Res Commun. 502:429–434. 2018. View Article : Google Scholar : PubMed/NCBI
37	Mann MK, Zepeda-Velázquez CA, González-Álvarez H, Dong A, Kiyota T, Aman AM, Loppnau P, Li Y, Wilson B, Arrowsmith CH, et al: Structure-activity relationship of USP5 inhibitors. J Med Chem. 64:15017–15036. 2021. View Article : Google Scholar : PubMed/NCBI
38	Kapuria V, Peterson LF, Showalter HDH, Kirchhoff PD, Talpaz M and Donato NJ: Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity. Biochem Pharmacol. 82:341–349. 2011. View Article : Google Scholar : PubMed/NCBI
39	Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M and Donato NJ: Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res. 70:9265–9276. 2010. View Article : Google Scholar : PubMed/NCBI
40	Li J, Li H, Zhu W, Zhou B, Ying J, Wu J, Zhang H, Sun H and Gao S: Deubiquitinase inhibitor degrasyn suppresses metastasis by targeting USP5-WT1-E-cadherin signalling pathway in pancreatic ductal adenocarcinoma. J Cell Mol Med. 24:1370–1382. 2020. View Article : Google Scholar : PubMed/NCBI